Inspira Technologies Oxy (IINN) said Friday that it is preparing to ramp up production of its Inspira ART100 respiratory device amid the recent outbreak of human metapneumovirus, or hMPV, in China.
The company said it is in talks with providers in affected regions to evaluate demand for the device and is working with suppliers to secure the components. Inspira also said it will coordinate with health authorities and "adjust its plans based on the evolving situation."
Shares of Inspira Technologies Oxy were up 13% premarket.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。